{"nctId":"NCT00619359","briefTitle":"Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)","startDateStruct":{"date":"2008-02"},"conditions":["Chemotherapy-Induced Nausea and Vomiting (CINV)"],"count":2322,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: fosaprepitant dimeglumine","Drug: Dexamethasone","Drug: Ondansetron"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: Aprepitant","Drug: Dexamethasone","Drug: Ondansetron"]}],"interventions":[{"name":"Comparator: fosaprepitant dimeglumine","otherNames":[]},{"name":"Comparator: Aprepitant","otherNames":[]},{"name":"Dexamethasone","otherNames":[]},{"name":"Dexamethasone","otherNames":[]},{"name":"Ondansetron","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient is male or female and is at least 18 years of age; scheduled to receive his or her first course of cisplatin chemotherapy at a dose of 70 mg/m2 or higher; predicted life expectancy of 3 months or greater\n* Patient is post menopausal or, if premenopausal, must use double-barrier contraception\n\nExclusion Criteria:\n\n* Patient has symptomatic primary or metastatic CNS malignancy\n* Patient has received or will receive Radiation therapy to the abdomen or pelvis in the week prior to Treatment Day 1 though Day 6\n* Patient has vomited in the 24 hours prior to treatment Day 1\n* Patient has an active infection; Patient uses illicit drugs or has current evidence of alcohol abuse\n* Patient is pregnant or breast feeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).","description":"The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 120 hours following initiation of cisplatin chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"795","spread":null},{"groupId":"OG001","value":"820","spread":null}]}]}]},{"type":"SECONDARY","title":"A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).","description":"The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 25 to 120 hours following initiation of cisplatin chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"822","spread":null},{"groupId":"OG001","value":"841","spread":null}]}]}]},{"type":"SECONDARY","title":"No Vomiting Overall (in the 120 Hours Following Initiation of Cisplatin)","description":"The number of patients who reported No Vomiting in the 120 hours following initiation of cisplatin chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"806","spread":null},{"groupId":"OG001","value":"844","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":148,"n":1143},"commonTop":["Constipation","Asthenia","Diarrhoea","Anorexia","Nausea"]}}}